Another Scandal in Evidence-Based Medicine: Ambulatory BP Monitoring Questioned?

Apparently, the scandal surrounding the EXCEL trial kicked the hornet’s nest as far as evidence-based medicine is concerned. This time, the stars were the actual authors of an article published in the prestigious New England Journal of Medicine (NEJM): the investigators retracted their paper due to issues in data analysis.

Otro “escándalo” en la medicina basada en la evidencia ¿El monitoreo ambulatorio de presión puesto en duda?

The aforementioned work was originally published in 2018 in the most prestigious medical journal worldwide, and it showed that ambulatory blood pressure monitoring readings were strongly associated with mortality. In that sense, the association was stronger than with readings obtained at the doctor’s office.

At the time, the lead author had mentioned that his work was the largest worldwide and provided unequivocal evidence that [ambulatory blood pressure monitoring] is superior to clinic pressure at predicting total and cardiovascular mortality. This week, the authors themselves retracted the article due to problems in statistical analyses.


Read also: Latest Guidelines “Dropped” After Scandal Over EXCEL Results.


Now, an independent statistical team is working with the aim of publishing the results as soon as possible.

The original suspicion was confirmed when researchers attempted to replicate findings in the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes.


Read also: Treating Both Atrial Valves Improves Survival.


Despite everything, ambulatory blood pressure monitoring is still the most suitable method to diagnose and manage hypertension.

2020-03-09-banegas2018 2020-03-09-nejmc2001445

Original title: Retraction: Relationship between clinic and ambulatory blood-pressure measurements a. nd mortality.

Reference: Banegas JR et al. N Engl J Med. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....